3 recruiting, 3 terminated, 3 unknown, 1 completed. 4 Phase 1, 3 Phase 2, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 3, Recruiting 1 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
| Not applicable | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Ovary Neoplasm: new trials by email Literature Review of Ovary Neoplasm trials Research Report on Ovary Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Tart Cherry Juice - Breast Cancer, Breast Cancer Stage I | Phase 2 | Recruiting | University of California, Davis | 86 | 2024-08-15 | 2026-03-04 |
| Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine - Ovary Neoplasm, Ovarian Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-29 | 2026-05-19 |
| SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours Blood test, Pathology specimen miRNA expression - Germ Cell Ovarian Cancer, Germ Cell Tumor | Not yet recruiting | Imperial College London | 24 | 2024-04-14 | 2024-03-26 | |
| Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs Neoantigen specific TCR-T cell drug product - Gynecologic Cancer, Colorectal Cancer | Completed | Alaunos Therapeutics | 8 | 2022-10-07 | 2026-10-15 | |
| Safety, Effectiveness and Operability of Using the New Tissue Containment System During Laparoscopic Ovarian Cystectomy the New Tissue Containment System - Ovary Neoplasm, Surgery | Not applicable | Unknown | China-Japan Friendship Hospital | 400 | 2022-05-20 | 2022-10-26 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) - Gynecologic Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 8 | 2022-04-04 | 2025-11-10 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| Registry Platform Ovarian and Endometrial Cancer Physician's choice according to patient's needs. - Ovarian Cancer, Endometrial Cancer | Recruiting | iOMEDICO AG | 1975 | 2021-11-25 | 2026-01-28 | |
| Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer chemotherapy, targeted therapeutics, immunotherapy, IFRT, IMRT or SBRT - Ovarian Cancer, Neoplasm, Ovarian | Not applicable | Unknown | Xi'an Jiaotong University | 150 | 2021-10-10 | 2021-09-28 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer HIPEC, CRS, IVCT - Ovarian Cancer, Ovary Neoplasm | Phase 3 | Unknown | Zhongnan Hospital | 112 | 2017-09-30 | 2020-05-29 |
Ovarian Neoplasms (11) · Carcinoma, Ovarian Epithelial (3) · Endometrial Neoplasms (3) · Pancreatic Neoplasms (3) · Recurrence (3) · Adenocarcinoma of Lung (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Carcinoma, Endometrioid (1) · Fallopian Tube Neoplasms (1) · Krukenberg Tumor (1) · Neoplasm Metastasis (1)
Adnexal Diseases (11) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Genital Diseases, Female (11) · Genital Neoplasms, Female (11) · Gonadal Disorders (11) · Neoplasms by Site (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Neoplasms (10) · Ovarian Diseases (10) · Neoplasms by Histologic Type (7)
Cyclophosphamide (1) · Drug Therapy (1) · Hematologic Tests (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Immunotherapy (1) · Interleukin-2 (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · aldesleukin (1) · enzalutamide (1) · fludarabine (1) · fludarabine phosphate (1) · olaparib (1)
Alaunos Therapeutics (2) · China-Japan Friendship Hospital (1) · Elucida Oncology (1) · Imperial College London (1) · Nuvation Bio Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, Davis (1) · Xi'an Jiaotong University (1) · Zhongnan Hospital (1) · iOMEDICO AG (1)
United States (6) · China (3) · Australia (1) · Germany (1)
Scott Kopetz, MD, PhD (2) · Anja Welt, Dr. (1) · Dirk Watermann, Prof.Dr. (1) · Elmar Stickeler, Prof.Dr. (1) · Eve Rodler, MD (1) · Linda Van Le, MD (1) · Srdjan Saso, PhD MRCOG MRCS (1) · Thomas Decker, Prof.Dr. (1) · Zi Liu, Ph.d (1)